FDA Advisory Panel Rejects Acadia’s Antipsychotic for Alzheimer’s

Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

The U.S. Food and Drug Administration advisory panel voted against the approval of Acadia Pharmaceutical’s drug for hallucinations and delusions associated with Alzheimer’s disease psychosis on Friday.

The advisory voted 3 to 9 with no abstention after eight hours of discussion. The panel concluded that the studies were not enough to support the efficacy of Acadia Pharmaceutical’s pimavanserin (trading as Nuplazid), against Alzheimer’s disease psychosis (ADP).